The Claim

Once-weekly subcutaneous semaglutide at a dose of 2.4 mg results in resolution of steatohepatitis without worsening of liver fibrosis in approximately 62.9% of patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage 2 or 3, compared to 34.3% with placebo, representing an absolute difference of 28.7 percentage points (95% CI, 21.1 to 36.2; P<0.001) at 72 weeks of treatment.

Source: Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
88score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

Patients with MASH and liver fibrosis who received weekly semaglutide injections had a 62.9% rate of steatohepatitis resolution without worsening fibrosis, significantly higher than the 34.3% rate in the placebo group over 72 weeks.

See the scientific wording

Once-weekly subcutaneous semaglutide at a dose of 2.4 mg causes resolution of steatohepatitis without worsening of liver fibrosis in approximately 62.9% of patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage 2 or 3, compared to 34.3% with placebo, representing an absolute difference of 28.7 percentage points (95% CI, 21.1 to 36.2; P<0.001) at 72 weeks of treatment.

Why this might work

Semaglutide helps the liver by lowering fat and inflammation. This stops the production of harmful fats called ceramides and a substance called oxalate that damage liver cells. As a result, liver swelling goes away without making scarring worse.

Suggested mechanismbased on 1 study

What the research says

1 study
  1. Study: Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

    The study found that semaglutide helps about 63 out of 100 people with fatty liver disease reverse liver inflammation without making scarring worse, which matches the claim exactly.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.